Trial Profile
Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2013
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 13 Aug 2012 Actual end date (1 Jun 2012)added as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 01 May 2012 Planned end date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.